Thrombin and Coagulation Factor Xa (FIIa/IIa, FXa/Xa)

Thrombin (coagulation factor IIa) and coagulation factor Xa are essential serine proteases in the blood coagulation cascade. Factor Xa is produced when its precursor, factor X, is activated by the intrinsic or extrinsic pathway. Factor Xa forms the prothrombinase complex with factor Va, calcium, and phospholipids, catalyzing the conversion of prothrombin to thrombin[1][3][7][5]. Thrombin then converts soluble fibrinogen to insoluble fibrin, resulting in clot formation; it also activates platelets and various cofactors, amplifying the haemostatic response[7][2][5]. Both enzymes also participate in cellular signaling (primarily via proteinase-activated receptors), contributing to inflammation, tissue repair, and disease progression beyond haemostasis[6][5]. Due to their central roles, both are validated targets for modern orally available anticoagulants and parenteral agents, including factor Xa and thrombin inhibitors. Their activity and inhibition are clinically monitored using specialized assays such as aPTT and anti-Xa[4][8]. Safety concerns include bleeding risk, drug interactions, and specific monitoring issues.

Other names

ProthrombinFactor IIFIIcoagulation factor IIaFactor XStuart-Prower factorFXaXactivated Factor XStuart factor

Direct inhibition of active site: small molecule inhibitors bind directly to thrombin or FXa, blocking enzymatic activity (dabigatran for thrombin, rivaroxaban/apixaban/edoxaban/betrixaban for FXa). Indirect inhibition by antithrombin potentiation (heparins bind antithrombin, which then inhibits thrombin and factor Xa). Prodrug conversion: Some oral agents are prodrugs that convert in the body to active inhibitors.